Initiate a pharmacokinetic run-in study in adolescents
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Aug 2024
- Due
- 31 Dec 2024
- Delivered
- January 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Planning initiation of pharmacokinetic (PK) run-in study in adolescents by year-end 2024”
What we found
Evidence strength A What the grades mean
The company planned to initiate the adolescent PK run-in study by year-end 2024, but filings confirm the study dosing was initiated in January 2025.
-
A Larimar Therapeutics, Inc. 10-Q filed 2025-04-30
“In January 2025, the Company initiated dosing of adolescents (12-17 years old) in a pharmacokinetic ("PK") run-in study for pediatric patients with FA.” ✓ confirmed on the page
Market reaction: the shares moved +22.0% against the S&P 500 over the three sessions around the disclosure (29 Apr 2025 to 2 May 2025). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Language weakened: firm → expected
- 3 versions
-
Version 1 · original · stated 7 Aug 2024
Deadline 31 Dec 2024 (“by year-end 2024”)
-
Version 2 · stated 30 Oct 2024
Deadline 31 Dec 2024 (“by year-end 2024”) · target 15 adolescents · wording firm
“Larimar is on track to initiate by year-end a PK run-in study in an initial cohort of 12-15 adolescents”
-
Version 3 · stated 30 Oct 2024
Deadline 31 Dec 2024 (“by end of 2024”) · wording expected
“Plans to initiate PK run-in study in adolescents by end of 2024”
-
Version 4 · stated 16 Dec 2024
Deadline 31 Mar 2025 (“early 2025”) · target 50 mg · wording expected
“Dosing expected to initiate in early 2025 at weight-based dose equivalent dose of adult 50 mg dose”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- pharmacokinetic run-in study in adolescents
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LRMR-003001 · Corrections policy